메뉴 건너뛰기




Volumn 251, Issue 3, 2013, Pages 697-704

Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration

Author keywords

Intravitreal injection; Neovascular age related macular degeneration; Optical coherence tomography; P.R.N. treatment regimen; Predictability; Ranibizumab

Indexed keywords

RANIBIZUMAB;

EID: 84877130218     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2090-9     Document Type: Article
Times cited : (52)

References (21)
  • 1
    • 1942542429 scopus 로고    scopus 로고
    • Age-related macular degeneration is the leading cause of blindness
    • 15108691 10.1001/jama.291.15.1900 1:CAS:528:DC%2BD2cXjsVajt70%3D
    • Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291:1900-1901
    • (2004) JAMA , vol.291 , pp. 1900-1901
    • Bressler, N.M.1
  • 4
    • 57949094834 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    • 19118696 10.1016/j.ophtha.2008.10.018
    • Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116:57-65
    • (2009) Ophthalmology , vol.116 , pp. 57-65
    • Brown, D.M.1    Michels, M.2    Kaiser, P.K.3    Heier, J.S.4    Sy, J.P.5    Ianchulev, T.6
  • 6
    • 77956056292 scopus 로고    scopus 로고
    • Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2
    • 20598667 10.1016/j.ajo.2010.04.011 1:CAS:528:DC%2BC3cXhtVGmt7%2FI
    • Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315-324
    • (2010) Am J Ophthalmol , vol.150 , pp. 315-324
    • Abraham, P.1    Yue, H.2    Wilson, L.3
  • 7
    • 38349172455 scopus 로고    scopus 로고
    • Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
    • 18222192 10.1016/j.ajo.2007.10.004 1:CAS:528:DC%2BD1cXhtV2hsr4%3D
    • Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239-248
    • (2008) Am J Ophthalmol , vol.145 , pp. 239-248
    • Regillo, C.D.1    Brown, D.M.2    Abraham, P.3    Yue, H.4    Ianchulev, T.5    Schneider, S.6    Shams, N.7
  • 8
    • 33947403618 scopus 로고    scopus 로고
    • An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
    • 17386270 10.1016/j.ajo.2007.01.028 1:CAS:528:DC%2BD2sXjsVWitb8%3D
    • Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566-583
    • (2007) Am J Ophthalmol , vol.143 , pp. 566-583
    • Fung, A.E.1    Lalwani, G.A.2    Rosenfeld, P.J.3    Dubovy, S.R.4    Michels, S.5    Feuer, W.J.6    Puliafito, C.A.7    Davis, J.L.8    Flynn, Jr.H.W.9    Esquiabro, M.10
  • 9
    • 46749113999 scopus 로고    scopus 로고
    • Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration
    • 18617755 10.1159/000144075 1:CAS:528:DC%2BD1cXhtFart7jI
    • Mantel I, Zografos L, Ambresin A (2008) Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 222:321-323
    • (2008) Ophthalmologica , vol.222 , pp. 321-323
    • Mantel, I.1    Zografos, L.2    Ambresin, A.3
  • 10
    • 78049267612 scopus 로고    scopus 로고
    • Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy
    • 20517175 10.1097/IAE.0b013e3181d50cbf
    • Engelbert M, Zweifel SA, Freund KB (2010) Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 30:1368-1375
    • (2010) Retina , vol.30 , pp. 1368-1375
    • Engelbert, M.1    Zweifel, S.A.2    Freund, K.B.3
  • 11
    • 78049279239 scopus 로고    scopus 로고
    • A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact
    • 20591490 10.1016/j.ophtha.2010.02.032
    • Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:2134-2140
    • (2010) Ophthalmology , vol.117 , pp. 2134-2140
    • Gupta, O.P.1    Shienbaum, G.2    Patel, A.H.3    Fecarotta, C.4    Kaiser, R.S.5    Regillo, C.D.6
  • 12
    • 79955588731 scopus 로고    scopus 로고
    • Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration
    • 21170547 10.1007/s00417-010-1588-2
    • Horster R, Ristau T, Sadda SR, Liakopoulos S (2011) Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249:645-652
    • (2011) Graefes Arch Clin Exp Ophthalmol , vol.249 , pp. 645-652
    • Horster, R.1    Ristau, T.2    Sadda, S.R.3    Liakopoulos, S.4
  • 13
    • 78651371501 scopus 로고    scopus 로고
    • Inject and extend dosing versus dosing as needed: A comparative retrospective study of ranibizumab in exudative age-related macular degeneration
    • 20890246 10.1097/IAE.0b013e3181de5609 1:CAS:528:DC%2BC38Xjt1ahtr0%3D
    • Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26-30
    • (2011) Retina , vol.31 , pp. 26-30
    • Oubraham, H.1    Cohen, S.Y.2    Samimi, S.3    Marotte, D.4    Bouzaher, I.5    Bonicel, P.6    Fajnkuchen, F.7    Tadayoni, R.8
  • 14
    • 13944266313 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration
    • 15671306 10.1167/iovs.04-0601
    • Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726-733
    • (2005) Invest Ophthalmol Vis Sci , vol.46 , pp. 726-733
    • Gaudreault, J.1    Fei, D.2    Rusit, J.3    Suboc, P.4    Shiu, V.5
  • 15
    • 0032864292 scopus 로고    scopus 로고
    • Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
    • 10528633 10.1177/019262339902700507 1:CAS:528:DyaK1MXmsFyntLo%3D
    • Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536-544
    • (1999) Toxicol Pathol , vol.27 , pp. 536-544
    • Mordenti, J.1    Cuthbertson, R.A.2    Ferrara, N.3    Thomsen, K.4    Berleau, L.5    Licko, V.6    Allen, P.C.7    Valverde, C.R.8    Meng, Y.G.9    Fei, D.T.10    Fourre, K.M.11    Ryan, A.M.12
  • 16
    • 34249914760 scopus 로고    scopus 로고
    • Ranibizumab
    • 17521219 10.2165/00003495-200767080-00007 1:CAS:528:DC%2BD2sXot1Sgtbc%3D
    • Blick SK, Keating GM, Wagstaff AJ (2007) Ranibizumab. Drugs 67:1199-1206
    • (2007) Drugs , vol.67 , pp. 1199-1206
    • Blick, S.K.1    Keating, G.M.2    Wagstaff, A.J.3
  • 17
    • 69249213449 scopus 로고    scopus 로고
    • Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration
    • 19643484 10.1016/j.ophtha.2009.05.033
    • Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740-1747
    • (2009) Ophthalmology , vol.116 , pp. 1740-1747
    • Dadgostar, H.1    Ventura, A.A.2    Chung, J.Y.3    Sharma, S.4    Kaiser, P.K.5
  • 18
    • 79955639955 scopus 로고    scopus 로고
    • Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome
    • 21387180 10.1007/s00417-011-1636-6 1:CAS:528:DC%2BC3MXltlKjt70%3D
    • Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M (2011) Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 249:653-662
    • (2011) Graefes Arch Clin Exp Ophthalmol , vol.249 , pp. 653-662
    • Gerding, H.1    Loukopoulos, V.2    Riese, J.3    Hefner, L.4    Timmermann, M.5
  • 19
    • 77953580546 scopus 로고    scopus 로고
    • Safety and efficacy of ranibizumab treatment in patients with neovascular age-related macular degeneration: 12-Month results of the SUSTAIN study
    • on behalf of the SUSTAIN study group E-Abstract 3095
    • Holz FG, Meyer C, Eter N, on behalf of the SUSTAIN study group (2009) Safety and efficacy of ranibizumab treatment in patients with neovascular age-related macular degeneration: 12-Month results of the SUSTAIN study. Invest Ophthalmol Vis Sci 50: E-Abstract 3095
    • (2009) Invest Ophthalmol Vis Sci , vol.50
    • Holz, F.G.1    Meyer, C.2    Eter, N.3
  • 20
    • 67149101784 scopus 로고    scopus 로고
    • A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study
    • 19376495 10.1016/j.ajo.2009.01.024 1:CAS:528:DC%2BD1MXnsV2ru7g%3D
    • Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43-58
    • (2009) Am J Ophthalmol , vol.148 , pp. 43-58
    • Lalwani, G.A.1    Rosenfeld, P.J.2    Fung, A.E.3    Dubovy, S.R.4    Michels, S.5    Feuer, W.6    Davis, J.L.7    Flynn, Jr.H.W.8    Esquiabro, M.9
  • 21
    • 79956218863 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration
    • 21526923 10.1056/NEJMicm1005605 1:CAS:528:DC%2BC3MXmsFKhsrc%3D
    • Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
    • (2011) N Engl J Med , vol.364 , pp. 1897-1908
    • Martin, D.F.1    Maguire, M.G.2    Ying, G.S.3    Grunwald, J.E.4    Fine, S.L.5    Jaffe, G.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.